Teaching Collection

LA and Mitral Valve Hemodynamics

Morton J. Kern, MD, MSCAI, FACC, FAHA
06/18/2020

Related Content

beta blockers
Stopping Beta-Blockers After Heart Attack Safe for Low-Risk Patients
04/02/2026
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected...
04/02/2026
Cath Lab Digest
AI Predictive Value
Including AI-Derived Heart Fat Measurement Improves Accuracy of Cardiovascular Disease Risk Prediction
04/02/2026
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000...
04/02/2026
Cath Lab Digest
Tricuspid Valve Intervention
Two-Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
03/30/2026
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
The new TRISCEND II trial data...
03/30/2026
Cath Lab Digest
Getinge iCast covered stent
Covered Stents
Getinge’s iCast Covered Stent System Expands U.S. Offering With Additional Sizes
03/27/2026
Getinge has received U.S. FDA Premarket Approval (PMA) for additional sizes of its iCast covered stent system, expanding treatment options for patients with occlusive disease. The approval includes a new 10 mm diameter by 59 mm length, new 32...
Getinge has received U.S. FDA Premarket Approval (PMA) for additional sizes of its iCast covered stent system, expanding treatment options for patients with occlusive disease. The approval includes a new 10 mm diameter by 59 mm length, new 32...
Getinge has received U.S. FDA...
03/27/2026
Cath Lab Digest

Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

beta blockers
Stopping Beta-Blockers After Heart Attack Safe for Low-Risk Patients
04/02/2026
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected...
04/02/2026
Cath Lab Digest
AI Predictive Value
Including AI-Derived Heart Fat Measurement Improves Accuracy of Cardiovascular Disease Risk Prediction
04/02/2026
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000...
04/02/2026
Cath Lab Digest
Leapfrog Group ASC Reporting
Ambulatory Surgery Center Reporting
The Leapfrog Group Announces Major Expansion of its ASC Public Reporting Program
04/02/2026
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
In July, Leapfrog will publicly...
04/02/2026
Cath Lab Digest
PCSK9 Inhibitors
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
03/31/2026
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
Treatment with enlicitide...
03/31/2026
Cath Lab Digest
ACC 2026
Medtronic ALERT Study Reveals AI-Enabled Clinician Alerts Significantly Improve Evaluation and Valve Intervention for Patients With Heart Valve Disease 
03/30/2026
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.
The study utilized Tempus Next,...
03/30/2026
Cath Lab Digest
Roxana Mehran, MD
ACC 2026
Mount Sinai’s Roxana Mehran, MD, named President of the American College of Cardiology
03/30/2026
The American College of Cardiology (ACC) has named Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI, as its new President.
The American College of Cardiology (ACC) has named Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI, as its new President.
The American College of...
03/30/2026
Cath Lab Digest
Tricuspid Valve Intervention
Two-Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
03/30/2026
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
The new TRISCEND II trial data...
03/30/2026
Cath Lab Digest
ACC 2026
Landmark ALL-RISE Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment
03/30/2026
In a statement, Drs. Martin Leon, Ajay Kirtane, William Fearon, and Allen Jeremias stated: "The compelling results should serve as the impetus to increase adoption of physiology worldwide."
In a statement, Drs. Martin Leon, Ajay Kirtane, William Fearon, and Allen Jeremias stated: "The compelling results should serve as the impetus to increase adoption of physiology worldwide."
In a statement, Drs. Martin...
03/30/2026
Cath Lab Digest
ACC 2026
Boston Scientific Presents Two Late-Breaking Trials at ACC 2026 Highlighting New Evidence in Stroke Prevention for AFib and Treatment of Intermediate-Risk Pulmonary Embolism
03/30/2026
At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
At the American College of...
03/30/2026
Cath Lab Digest
Prevalence of hypercortisolism in resistant hypertension patients from the MOMENTUM Study – credit Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital
Resistant Hypertension
Nearly 30 Percent of Patients With Resistant Hypertension Have a Hormone Disorder Caused by High Cortisol
03/30/2026
MOMENTUM is described as the first U.S.-based study and the largest study to date to assess the prevalence of hypercortisolism among individuals with resistant hypertension. Researchers analyzed 1,086 participants across 50 centers in the...
MOMENTUM is described as the first U.S.-based study and the largest study to date to assess the prevalence of hypercortisolism among individuals with resistant hypertension. Researchers analyzed 1,086 participants across 50 centers in the...
MOMENTUM is described as the...
03/30/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use